Key result
Transcatheter mitral and tricuspid therapies show comparable success in women, with more bleeding but less AKI.
Why the study?
Women are under-represented in clinical trials, and in many trials, outcomes are not specified for sex despite rapid development of transcatheter mitral and tricuspid devices.
Do outcomes of transcatheter mitral and tricuspid therapy differ between female and male patients?
Do outcomes of transcatheter mitral and tricuspid therapy differ between female and male patients?
Transcatheter mitral and tricuspid interventions show good procedural results in women, though they experience more bleeding complications and less kidney injury compared to men.
Women may warrant closer periprocedural bleeding monitoring with transcatheter mitral/tricuspid therapies; hypothesis-generating and leaves open need for prospective sex-stratified trials.
Development of mitral and tricuspid devices has exploded, although the number of procedures is still limited. Women are under-represented in clinical trials, and in many trials, outcomes are not specified for sex. In mitral and tricuspid trials, the sex distribution is more even than in transcatheter aortic valve implantation (TAVI) trials. In these trials, in general, females are older, have more bleeding complications, and have less kidney injury than men. Procedural results are good. Long-term observation is still not available because of short observation time. In tricuspid procedures, other factors than device success play a role, like right heart failure, pulmonary hypertension, and atrial fibrillation. We should, for the future, focus more on differences in outcome between men and women to better customize treatment options. Graphical Abstract: Transcatheter mitral and tricuspid interventions, outcomes in women. Generated by AI.
No takes yet. Share an insight, caveat, or question.
Gry Dahle (2025) conducted a review in Mitral and tricuspid valve disease. Transcatheter mitral and tricuspid therapy vs. Male patients was evaluated. Transcatheter mitral and tricuspid therapies yield comparable procedural success in women and men, though women experience more bleeding complications and less acute kidney injury.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: